DUBLIN, Aug. 06, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zxx75f/investigation) has announced the addition of the "Investigation Report on China's Menotropins Market, 2010-2019" report to their offering.

According to the statistics, at present there are about 100 million women in the high-fertility period (aged 20-29) in China, over 12% of whom suffer from infertility. About 30% of female diagnosed with infertility suffer from ovulation inhibition. Herein it can be estimated that the number of potential patients suffering from ovulation inhibition is larger than 3.6 million. Popular clinic drugs utilized in the treatment of ovulation inhibition include clomifene citrate, and gonadotropin (mainly classified into follicle stimulating hormone, menotropins and chorionic gonadotrophin). Gonadotropin is usually utilized if clomifene citrate doesn't work , and sometimes utilized together with clomifene citrate to promote ovulation. chorionic gonadotrophin in combination with follicle stimulating hormone or menotrophins are often applied in the clinic . That is to say, the follicle stimulating hormone or menotrophins is utilized first to foster the growth and maturation of the follicle, and then chorionic gonadotrophin is utilized to stimulate ovulation and provide luteal support.

As one of the earliest ovulation stimulants utilized in the clinic , menotropins was utilized in the clinic as early as the 1960s. Extracted from urines of post-menopausal women, menotropins is mainly composed of 75IU ovulation stimulant and 75IU luteinizing hormone. It fosters the growth and maturation of ovulation and affiliates secretion of estrogen within the follicle. In China, there are plenty of manufacturers of menotropins. However, the quality of menotropins produced by these manufacturers is uneven. Menotropins produced by Livzon Pharmaceutical Group Inc, with high purity and outstanding quality, enjoys individual pricing of the development and reform committee, thus its bidding price is slightly higher than that of other manufacturers.

Menotropins has been growing at a rapid pace after entering the Chinese market, with its annual sales value rising from less than CNY 20 million in 2005 to CNY 79.1 million in 2014 and its CAGR from 2005 to 2014 reaching 22.8%. Chinese menotrohins market is mainly dominated by Livzon Pharmaceutical, Livzon Pharmaceutical Group, Inc, Ferring Pharmaceytical Co., Ltd (Germany), Ma'anshan Fengyuan Pharmaceutical Co., Ltd, Yantai North Pharmaceutical Co., Ltd and Shanghai Livzon Pharmaceutical Co., Ltd, among which Shanghai Livzon Pharmaceutical Co., Ltd owns the largest market share, market share for sales value exceeding 60% in 2004.

Key Topics Covered:

1 Related Concepts of Menotropins

2 Market Profile of Menotropins in China

3 Survey on Sales Status of Menotropins in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Menotropins in China, 2010-2014

5 Survey on Dosage Forms of Menotropins in China, 2010-2014

6 Reference Price of Menotropins in Chinese Hospitals in 2014

7 Major Manufacturers of Menotropins in Chinese Market, 2010-2014

8 Market Outlook of Menotropins in China, 2015-2019

Companies Mentioned

- Shanghai Livzon Pharmaceutical Co., Ltd,
- Livzon Pharmaceutical, Livzon Pharmaceutical Group Inc
- Yantai North Pharmaceutical Co., Ltd
- Ma'anshan Fengyuan Pharmaceutical Co., Ltd
- Ferring Pharmaceytical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/zxx75f/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets